Drug intelligence / Profile preview

erbstatin

Development stage: Unknown
Modality: Small Molecules

Overview

**Erbstatin** is a synthetic *tyrosine kinase inhibitor* originally identified as a selective inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase activity. It is typically used for research purposes rather than as a marketed pharmaceutical. Erbstatin blocks EGFR autophosphorylation and associated downstream signaling, thereby interfering with cellular proliferation and survival signals. Its primary applications are in cellular and biochemical studies investigating EGFR signaling pathways, cancer biology, and tyrosine kinase mechanisms.

Other names: erbstatin

Targets

PKA (Cyclic amp-dependent protein kinase)SFK (SRC family kinases)ERBB2 (Erb-b2 receptor tyrosine kinase 2)TOP2A (DNA topoisomerase II)TOP1 (DNA Topoisomerase I)

Beyond the preview

Go deeper on erbstatin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on erbstatin.

Explore the full profile